HBP — Helix Biopharma Cashflow Statement
0.000.00%
Last trade - 00:00
- CA$60.79m
- CA$60.08m
2019 July 31st | 2020 July 31st | 2021 July 31st | 2022 July 31st | 2023 July 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -7.53 | -8.56 | -8.04 | -6.56 | -6.29 |
Depreciation | |||||
Non-Cash Items | 0.397 | -0.365 | -1.41 | 0.935 | 0.564 |
Discontinued Operations | |||||
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 1.47 | -2.11 | -0.054 | -0.893 | 0.186 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -5.53 | -10.8 | -9.3 | -6.51 | -5.53 |
Capital Expenditures | -0.004 | -0.016 | 0 | — | -0.01 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | — | 1.72 | 2.02 | 0 | 0.005 |
Sale of Business | |||||
Sale of Fixed Assets | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -0.004 | 1.7 | 2.02 | 0 | -0.005 |
Financing Cash Flow Items | — | 1.06 | 0 | — | 0.999 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 5.41 | 13.1 | 6.56 | 6.21 | 3.09 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -0.16 | 4.03 | -0.67 | -0.313 | -2.44 |